These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

704 related items for PubMed ID: 18840485

  • 1. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
    Hong M, Zhu S, Jiang Y, Tang G, Pei Y.
    J Control Release; 2009 Jan 19; 133(2):96-102. PubMed ID: 18840485
    [Abstract] [Full Text] [Related]

  • 2. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
    Hong M, Zhu S, Jiang Y, Tang G, Sun C, Fang C, Shi B, Pei Y.
    J Control Release; 2010 Jan 04; 141(1):22-9. PubMed ID: 19735683
    [Abstract] [Full Text] [Related]

  • 3. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X, Ding L, Xu Y, Wang Y, Ping Q.
    Int J Pharm; 2009 May 21; 373(1-2):116-23. PubMed ID: 19429296
    [Abstract] [Full Text] [Related]

  • 4. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).
    Maruyama K, Ishida O, Kasaoka S, Takizawa T, Utoguchi N, Shinohara A, Chiba M, Kobayashi H, Eriguchi M, Yanagie H.
    J Control Release; 2004 Aug 11; 98(2):195-207. PubMed ID: 15262412
    [Abstract] [Full Text] [Related]

  • 5. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity.
    Shi B, Fang C, Pei Y.
    J Pharm Sci; 2006 Sep 11; 95(9):1873-87. PubMed ID: 16795003
    [Abstract] [Full Text] [Related]

  • 6. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY.
    Bioconjug Chem; 2007 Sep 11; 18(1):41-9. PubMed ID: 17226956
    [Abstract] [Full Text] [Related]

  • 7. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo.
    Hatakeyama H, Akita H, Maruyama K, Suhara T, Harashima H.
    Int J Pharm; 2004 Aug 20; 281(1-2):25-33. PubMed ID: 15288340
    [Abstract] [Full Text] [Related]

  • 8. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.
    Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ.
    Eur J Pharm Sci; 2006 Jan 20; 27(1):27-36. PubMed ID: 16150582
    [Abstract] [Full Text] [Related]

  • 9. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
    Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K.
    Int J Pharm; 2008 Jan 04; 346(1-2):143-50. PubMed ID: 17640835
    [Abstract] [Full Text] [Related]

  • 10. Transferrin-loaded nido-carborane liposomes: tumor-targeting boron delivery system for neutron capture therapy.
    Miyajima Y, Nakamura H, Kuwata Y, Lee JD, Masunaga S, Ono K, Maruyama K.
    Bioconjug Chem; 2006 Jan 04; 17(5):1314-20. PubMed ID: 16984142
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles.
    Huang M, Wu W, Qian J, Wan DJ, Wei XL, Zhu JH.
    Acta Pharmacol Sin; 2005 Dec 04; 26(12):1512-8. PubMed ID: 16297352
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
    Hao YL, Deng YJ, Chen Y, Wang KZ, Hao AJ, Zhang Y.
    J Pharm Pharmacol; 2005 Oct 04; 57(10):1279-87. PubMed ID: 16259756
    [Abstract] [Full Text] [Related]

  • 15. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.
    Maruyama K.
    Adv Drug Deliv Rev; 2011 Mar 18; 63(3):161-9. PubMed ID: 20869415
    [Abstract] [Full Text] [Related]

  • 16. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
    Han L, Huang R, Liu S, Huang S, Jiang C.
    Mol Pharm; 2010 Dec 06; 7(6):2156-65. PubMed ID: 20857964
    [Abstract] [Full Text] [Related]

  • 17. Stealth PEG-PHDCA niosomes: effects of chain length of PEG on niosomes in vitro complement consumption and phagocytic uptake.
    Shi B, Fang C, You MX, Hong MH, Pei YY.
    Yao Xue Xue Bao; 2005 Nov 06; 40(11):976-81. PubMed ID: 16499079
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
    Su Z, Shi Y, Xiao Y, Sun M, Ping Q, Zong L, Li S, Niu J, Huang A, You W, Chen Y, Chen X, Fei J, Tian J.
    Int J Pharm; 2013 Apr 15; 447(1-2):281-92. PubMed ID: 23396258
    [Abstract] [Full Text] [Related]

  • 20. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
    Xiang Y, Liang L, Wang X, Wang J, Zhang X, Zhang Q.
    J Control Release; 2011 Jun 30; 152(3):402-10. PubMed ID: 21435361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.